Sei Investments Co. grew its position in shares of Icon Plc (NASDAQ:ICLR) by 6.9% in the 4th quarter, HoldingsChannel.com reports. The fund owned 380,655 shares of the medical research company’s stock after purchasing an additional 24,572 shares during the quarter. Sei Investments Co.’s holdings in Icon were worth $65,553,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Cullen Frost Bankers Inc. boosted its holdings in shares of Icon by 452.5% during the fourth quarter. Cullen Frost Bankers Inc. now owns 221 shares of the medical research company’s stock valued at $38,000 after acquiring an additional 181 shares during the period. State Street Corp lifted its holdings in Icon by 4.0% in the fourth quarter. State Street Corp now owns 109,912 shares of the medical research company’s stock worth $18,930,000 after purchasing an additional 4,260 shares during the period. Hancock Whitney Corp lifted its holdings in Icon by 2.2% in the fourth quarter. Hancock Whitney Corp now owns 9,417 shares of the medical research company’s stock worth $1,622,000 after purchasing an additional 202 shares during the period. Polen Capital Management LLC lifted its holdings in Icon by 16.3% in the fourth quarter. Polen Capital Management LLC now owns 260,128 shares of the medical research company’s stock worth $44,802,000 after purchasing an additional 36,370 shares during the period. Finally, DAGCO Inc. lifted its holdings in Icon by 5.0% in the fourth quarter. DAGCO Inc. now owns 7,485 shares of the medical research company’s stock worth $1,289,000 after purchasing an additional 355 shares during the period. 85.41% of the stock is owned by institutional investors.

Icon stock remained flat at $$175.28 during midday trading on Friday. 125,632 shares of the company’s stock traded hands, compared to its average volume of 200,457. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.03 and a quick ratio of 2.03. The business’s 50 day simple moving average is $171.48 and its 200-day simple moving average is $158.25. Icon Plc has a 12-month low of $127.58 and a 12-month high of $176.98. The firm has a market capitalization of $9.46 billion, a P/E ratio of 26.32, a PEG ratio of 2.07 and a beta of 0.77.

ICLR has been the subject of several research analyst reports. UBS Group set a $160.00 price objective on shares of Icon and gave the stock a “hold” rating in a report on Friday, October 25th. Citigroup initiated coverage on shares of Icon in a report on Monday, January 6th. They issued a “neutral” rating and a $185.00 price objective for the company. BidaskClub raised shares of Icon from a “hold” rating to a “buy” rating in a report on Friday, January 17th. SunTrust Banks downgraded shares of Icon from a “buy” rating to a “hold” rating and upped their price objective for the stock from $170.00 to $182.00 in a report on Monday, January 27th. Finally, Zacks Investment Research downgraded shares of Icon from a “buy” rating to a “hold” rating in a report on Wednesday, January 29th. Seven analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $171.89.

About Icon

ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.

See Also: Capital Gains Distribution

Want to see what other hedge funds are holding ICLR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Icon Plc (NASDAQ:ICLR).

Institutional Ownership by Quarter for Icon (NASDAQ:ICLR)

Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.